Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30087650 | 1.00 | KDM1A (0.69) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL23630641 | 1.00 | KDM1A (0.69) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL4671925 | 1.00 | KDM1A (0.69) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL29375351 | 1.00 | KDM1A (0.69) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL30087639 | 1.00 | KDM1A (0.69) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL9973848 | 0.92 | KDM1A (0.67) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL4669878 | 0.92 | MEN1 (0.77) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL8640599 | 0.92 | MEN1 (0.77) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL9973830 | 0.91 | MEN1 (0.65) | KDM1AMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL35210122 | 0.89 | KDM1A (0.69) | KDM1AMEN1KMT2AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006117602-A2 | USE OF AMIDE DERIVATIVES AS TASTE-MODIFYING AGENTS, FLAVOURING COMPOSITIONS AND PRODUCTS CONTAINING THEM | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2006-11-09 | — | — | WO | claimed |
| US-12564551-B2 | Composition or oat extract comprising avenanthramide and β-glucan | SYMRISE AG (DE) | 2026-03-03 | — | — | US | disclosed |
| EP-4487838-A2 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | Symrise AG (DE) | 2025-01-08 | — | — | EP | disclosed |
| EP-4114354-B1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | SYMRISE AG (DE) | 2024-12-11 | — | — | EP | disclosed |
| CN-118078792-A | Application of avenanthramide in preventing and treating osteoporosis | 北京工商大学 | 2024-05-28 | — | — | CN | disclosed |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | SYMRISE AG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230124050-A1 | Composition or oat extract comprising avenanthramide and ß-glucan | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20230118435-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE WITH IMPROVED SKIN PENETRATION | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-4114353-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | Symrise AG (DE) | 2023-01-11 | — | — | EP | disclosed |
| EP-4114350-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE WITH IMPROVED SKIN PENETRATION | Symrise AG (DE) | 2023-01-11 | — | — | EP | disclosed |
| CN-115279333-A | Composition or oat extract comprising avenanthramide and beta-glucan | 西姆莱斯股份公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115243669-A | Avenanthramide compositions with enhanced solubility comprising 4-hydroxybenzophenones | 西姆莱斯股份公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115243670-A | Cosmetic or pharmaceutical use of avenanthramide L | 西姆莱斯股份公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115243664-A | Compositions comprising avenanthramides for increasing skin permeability | 西姆莱斯股份公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115209864-A | Compositions comprising avenanthramides or analogs thereof having improved stability | 西姆莱斯股份公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2021176074-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE WITH IMPROVED SKIN PENETRATION | SYMRISE AG (DE) | 2021-09-10 | — | — | WO | disclosed |
| US-20210212349-A1 | Consumable Product Comprising Malted Dehulled Oats | LANTMÄNNEN FUNCTIONAL FOODS AB (SE) | 2021-07-15 | — | — | US | disclosed |
| CN-112770643-A | Consumable product comprising malted de-hulled oats | 兰特门内保健食品公司 | 2021-05-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564551-B2 | Composition or oat extract comprising avenanthramide and β-glucan | CUTA, HLA-A, OAT | KDM1A 3410/4885MEN1 1127/4885KMT2A 2657/4885 |
| US-20230124050-A1 | Composition or oat extract comprising avenanthramide and ß-glucan | OAT, PIGS, HLA-A | KDM1A 4128/4885MEN1 268/4885KMT2A 3678/4885 |
| US-20210212349-A1 | Consumable Product Comprising Malted Dehulled Oats | AGL, OAT, FABP6 | KDM1A 2308/4885MEN1 2460/4885KMT2A 2760/4885 |
| US-20230129036-A1 | AVENANTHRAMIDE COMPOSITIONS WITH IMPROVED SOLUBILITY COMPRISING 4-HYDROXYPHENONE | HPD, CYP4A22, PAH | KDM1A 2723/4885MEN1 2409/4885KMT2A 2584/4885 |
| US-20230131993-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE OR AN ANALOGUE THEREOF WITH IMPROVED STABILITY | OAT, PIGS, HLA-A | KDM1A 3647/4885MEN1 376/4885KMT2A 2513/4885 |
| US-20230118435-A1 | COMPOSITION COMPRISING AN AVENANTHRAMIDE WITH IMPROVED SKIN PENETRATION | CUTA, ABCG2, MMP7 | KDM1A 3736/4885MEN1 1740/4885KMT2A 3984/4885 |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | TACR1, NPSR1, TACR2 | KDM1A 2650/4885MEN1 725/4885KMT2A 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.